Giordano Christopher Thomas's Form 4 filing
Tenax Therapeutics, Inc. (TENX) · filed Jul 14, 2026
- Accession no.
- 0001193125-26-303600
- Filed
- Jul 14, 2026, 7:29 PM ET
- Trade date
- Jul 13, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Giordano Christopher ThomasCIK 0001871714 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Common Stock | MOption exerciseDisposed | −219 | $0.00 | $0 | 218 | Direct | |
| Jul 13, 2026 | Common Stock | MOption exerciseDisposed | −8,500 | $0.00 | $0 | 1,241,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The aggregate exercise price was paid in cash.
Referenced by the price of 2 transactions in Table I.